Novartis today announced that it has completed effective July 31, 2015 the divestiture of its influenza vaccine unit to CSL Limited.
This marks the end of a series of transactions previously announced and completed,that are focusing Novartis on its three leading businesses of global scale - pharmaceuticals, generics and eye care.
Since April 2014, the influenza vaccines unit results have been reported under Discontinuing Operations in the Novartis consolidated financial statements.
